Panelists discuss how shared decision-making empowers patients when choosing between IV and SC administration routes.
Remibrutinib showed rapid and sustained efficacy in CSU, with significant symptom reduction by week 2, maintained over 52 weeks. The pooled analysis of REMIX-1 and REMIX-2 trials highlighted ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback